Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma

被引：0

作者：

I Sekine

H Nokihara

A Horiike

N Yamamoto

H Kunitoh

Y Ohe

T Tamura

T Kodama

N Saijo

机构：

[1] National Cancer Center Hospital,Divisions of Internal Medicine and Thoracic Oncology

[2] Tsukiji 5-1-1,undefined

[3] Chuo-ku,undefined

来源：

British Journal of Cancer | 2004年 / 90卷

关键词：

squamous cell carcinoma; paclitaxel; nedaplatin; lung cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The recommended phase II dose of paclitaxel 180 mg m−2 given as a 3-h infusion followed by nedaplatin 100 mg m−2 in a 1-h infusion every 3–4 weeks was determined in 52 chemo-naive patients with unresectable squamous cell carcinoma (SCC), with a promising response rate for lung SCC of 55%.

引用

页码：1125 / 1128

页数：3

共 50 条

[21] Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma
Hiroshi Kurita
Etsuhide Yamamoto
Shinichi Nozaki
Shigehito Wada
Isao Furuta
Masaru Miyata
Kenji Kurashina
Cancer Chemotherapy and Pharmacology, 2010, 65 : 503 - 508
[22] Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma
Strumberg, D
Erhard, J
Harstrick, A
Klaassen, U
Muller, C
Eberhardt, W
Wilke, H
Seeber, S
EUROPEAN JOURNAL OF CANCER, 1998, 34 (08) : 1290 - 1292
[23] Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study
Yamamoto, Kaichtro
Kokawa, Katsuji
Umesaki, Naohiko
Nishimura, Ryuichiro
Hasegawa, Kazuo
Konishi, Ikuo
Saji, Fumitaka
Nishida, Masato
Noguchi, Hiroshi
Takizawa, Ken
ONCOLOGY REPORTS, 2009, 21 (04) : 1005 - 1009
[24] Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer
Igawa, Satoshi
Otani, Sakiko
Nakahara, Yoshiro
Ryuge, Shinichiro
Hiyoshi, Yasuhiro
Fukui, Tomoya
Mitsufuji, Hisashi
Kubota, Masaru
Katagiri, Masato
Sato, Yuichi
Sasaki, Jiichiro
Masuda, Noriyuki
INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 45 - 52
[25] Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma
Adamo, V
Ferraro, G
Pergolizzi, S
Sergi, C
Laudani, A
Settineri, N
Alafaci, E
Scimone, A
Spano, F
Spitaleri, G
ORAL ONCOLOGY, 2004, 40 (05) : 525 - 531
[26] CONCURRENT CHEMORADIOTHERAPY WITH PACLITAXEL AND NEDAPLATIN FOLLOWED BY CONSOLIDATION CHEMOTHERAPY IN LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX: PRELIMINARY RESULTS OF A PHASE II STUDY
Zhang, Mei-Qin
Liu, Su-Ping
Wang, Xiang-E
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : 821 - 827
[27] Polymeric Micellar Paclitaxel Plus Cisplatin Combined With Tislelizumab as the First-Line Treatment of Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study
Li, Xiaoyou
Shi, Jiamin
Zhu, Jinghua
Zhu, Jingni
Yan, Fei
Liu, Delin
Cao, Guochun
THORACIC CANCER, 2025, 16 (07)
[28] Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
Yun, Tak
Han, Ji-Youn
Lee, Jin Soo
Choi, Hyun Lee
Kim, Hyae Young
Nam, Byung-Ho
Kim, Heung Tae
BMC CANCER, 2011, 11
[29] Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: A phase I trial (GASTO-1021)
Chen, Nai-Bin
Li, Qi-Wen
Li, Su
Guo, Su-Ping
Wu, Ying-Jia
Cheng, Zhangkai J.
Li, Ji-Bin
Wang, Da-Quan
Liu, Fang-Jie
Ai, Xin-Lei
Hu, Nan
Qiu, Bo
Liu, Hui
RADIOTHERAPY AND ONCOLOGY, 2021, 155 : 105 - 112
[30] Phase I Study of Combination Chemotherapy Consisting of Paclitaxel, Cisplatin, and S-1 in Patients with Unresectable Gastric Cancer (KOGC-02)
Takahashi, Tsunehiro
Saikawa, Yoshiro
Fukuda, Kazumasa
Funakoshi, Shinsuke
Kawakubo, Hirofumi
Takeuchi, Hiroya
Takaishi, Hiromasa
Kitagawa, Yuko
ANTICANCER RESEARCH, 2012, 32 (12) : 5401 - 5406

← 1 2 3 4 5 →